Holistic Financial Partners Sells 109 Shares of Eli Lilly and Company (NYSE:LLY)

Holistic Financial Partners trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,714 shares of the company’s stock after selling 109 shares during the period. Eli Lilly and Company accounts for approximately 26.0% of Holistic Financial Partners’ investment portfolio, making the stock its biggest position. Holistic Financial Partners’ holdings in Eli Lilly and Company were worth $52,276,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Northwest Capital Management Inc increased its holdings in shares of Eli Lilly and Company by 9.5% in the fourth quarter. Northwest Capital Management Inc now owns 219 shares of the company’s stock valued at $169,000 after purchasing an additional 19 shares during the last quarter. Crestwood Advisors Group LLC increased its holdings in shares of Eli Lilly and Company by 1.0% in the fourth quarter. Crestwood Advisors Group LLC now owns 36,050 shares of the company’s stock valued at $27,830,000 after purchasing an additional 364 shares during the last quarter. IFP Advisors Inc increased its holdings in shares of Eli Lilly and Company by 32.1% in the fourth quarter. IFP Advisors Inc now owns 13,991 shares of the company’s stock valued at $10,806,000 after purchasing an additional 3,400 shares during the last quarter. Hardman Johnston Global Advisors LLC increased its holdings in shares of Eli Lilly and Company by 100.3% in the fourth quarter. Hardman Johnston Global Advisors LLC now owns 18,723 shares of the company’s stock valued at $14,454,000 after purchasing an additional 9,376 shares during the last quarter. Finally, RWC Asset Management LLP increased its holdings in shares of Eli Lilly and Company by 12.2% in the fourth quarter. RWC Asset Management LLP now owns 487 shares of the company’s stock valued at $376,000 after purchasing an additional 53 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Bank of America reiterated a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Barclays decreased their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Wolfe Research initiated coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective on the stock. Finally, Citigroup reduced their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,000.28.

Eli Lilly and Company Trading Up 0.1 %

LLY opened at $874.12 on Monday. The stock has a market capitalization of $828.82 billion, a price-to-earnings ratio of 74.65, a P/E/G ratio of 1.40 and a beta of 0.42. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The company has a 50-day simple moving average of $801.33 and a 200 day simple moving average of $847.66.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.69%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is 51.24%.

Eli Lilly and Company declared that its board has approved a share repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.